Success Metrics

Clinical Success Rate
88.9%

Based on 8 completed trials

Completion Rate
89%(8/9)
Active Trials
1(7%)
Results Posted
75%(6 trials)
Terminated
1(7%)

Phase Distribution

Ph not_applicable
1
7%
Ph phase_2
6
43%
Ph phase_4
2
14%
Ph phase_1
3
21%
Ph phase_3
2
14%

Phase Distribution

3

Early Stage

6

Mid Stage

4

Late Stage

Phase Distribution14 total trials
Phase 1Safety & dosage
3(21.4%)
Phase 2Efficacy & side effects
6(42.9%)
Phase 3Large-scale testing
2(14.3%)
Phase 4Post-market surveillance
2(14.3%)
N/ANon-phased studies
1(7.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.0%

8 of 10 finished

Non-Completion Rate

20.0%

2 ended early

Currently Active

1

trials recruiting

Total Trials

14

all time

Status Distribution
Active(1)
Completed(8)
Terminated(2)
Other(3)

Detailed Status

Completed8
unknown3
Withdrawn1
Active, not recruiting1
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
14
Active
1
Success Rate
88.9%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (21.4%)
Phase 26 (42.9%)
Phase 32 (14.3%)
Phase 42 (14.3%)
N/A1 (7.1%)

Trials by Status

withdrawn17%
completed857%
unknown321%
active_not_recruiting17%
terminated17%

Recent Activity

Clinical Trials (14)

Showing 14 of 14 trials
NCT04045379Not Applicable

LASER and Radiofrequency and Genitourinary Syndrome of Menopause

Active Not Recruiting
NCT03116022Phase 1

Use of Estriol at Distal Third of Vagina Improving Coital Pain in Post-menopause Women

Completed
NCT04159493Phase 2

A Randomized Controlled Phase 2 Study to Determine Lowest Efficacious Dose of Ovestin in Vulvar and Vaginal Atrophy

Withdrawn
NCT04574999Phase 3

Study to Determine Efficacy & Safety of a Low Concentration Estriol (0.005%) in Postmenopausal Vaginal Atrophy.

Completed
NCT01466114Phase 2

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

Unknown
NCT02967510Phase 2

Study Evaluating the Efficacy and Safety of Three Formulations of Ultra-low Dose Estriol Vaginal Gel (0.005%, 0.002%, 0.0008% Estriol Vaginal Gel) for the Treatment of Vaginal Dryness in Postmenopausal Women With Vulvovaginal Atrophy

Completed
NCT02413008Phase 2

A Clinical Trial to Assess the Safety of 0.005 % Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting

Completed
NCT03032848Phase 4

Vaginal Estrogens Comparative Trial on Pelvic Organ Prolapse Patients

Completed
NCT01408030Phase 2

North American Study of Epistaxis in Hereditary Hemorrhagic Telangiectasia (HHT)

Completed
NCT00816556Phase 3

A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis

Terminated
NCT02906111Phase 4

Vaginal Estriol Before and Vaginal Surgery for Prolapse

Unknown
NCT00451204Phase 2

A Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)

Completed
NCT02733731Phase 1

The Treatment Effect of Chinese Herbal Compound Ointment on Atrophic Vaginitis

Unknown
NCT00908570Phase 1

Topical Estriol for Vaginal Health

Completed

All 14 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
14